This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Fampridine-PR for multiple sclerosis, impaired mobility – first line

< Back

Fampridine-PR for multiple sclerosis, impaired mobility – first line


Neurology and Neurosurgery

May 2010

Fampridine-PR (Ampyra; fampridine-SR; fampridine-ER; dalfampridine; 4-AP; 4-aminopyridine) is a prolonged release, orally administered, potassium channel blocker. It has been shown to improve conduction across central demyelinated nerve fibres or axons. It is intended for the treatment of MS related walking and mobility problems. Fampridine-PR is administered orally at 10mg twice daily (12 hours apart) as monotherapy or in combination with existing therapies, including DMT agents.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

PDF Report


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts